Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Amgen takes to Europe with its Humira biosimilar

Damian Garde Amgen submitted its copy of AbbVie's blockbuster Humira to European regulators, angling to siphon revenues from the world's top-selling drug as rivals develop biosimilars ...

The most popular FiercePharma stories of 2015

Alok Saboo FiercePharma News

Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus

John Carroll Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" ...

Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents

Eric Palmer Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...

Daiichi Sankyo’s cancer drug wins the FDA’s coveted ‘breakthrough’ tag

Damian Garde Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it ...

Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott

Eric Palmer Allergan has been trying for months to resolve bribery allegations that came with its $ 8.5 billion buyout of Warner Chilcott and now will do that with a plea deal ...

U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...

Deerfield leads a $75M round for Akari

John Carroll FierceBiotech News

HIV activists join Janssen’s story-focused Prezcobix effort

Beth Snyder Bulik Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with ...

COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a ‘moron’ would ask

John Carroll FierceBiotech News

Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D

Damian Garde Antibiotics biotech Nabriva Therapeutics executed a $ 92.3 million IPO, pricing well below its projected range but scraping together the funds it needs to start a Phase ...
Page 3 of 9812345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS